Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has resubmitted its New Drug Application for STS101, a treatment for acute migraine, to the FDA, addressing previous concerns about formulation while receiving no requests for additional clinical trials. This move is seen as pivotal in offering new options for migraine sufferers.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.